Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04125836 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
A Phase 3 study, sponsored by Camurus AB.
- Completed
- Registry status
- Phase 3
- Development phase
- 135
- Enrollment target
NCT04125836 is a Phase 3 study that has completed, run by Camurus AB. The registered enrollment target is 135 participants.
The verdict
NCT04125836, a Phase 3 study, has completed, sponsored by Camurus AB.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial. Patients completing the main part of the trial will be offered 52 weeks continued open-label treatment in an extension part.
Interventions
- DRUG CAM2029 (octreotide subcutaneous depot)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2019-10-10 |
| Est. Completion | 2025-04-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04125836
The ClinicalTrials.gov registry entry for NCT04125836 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Camurus AB, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAM2029 (octreotide subcutaneous depot) is the first listed.
NCT04125836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04125836 about?
NCT04125836 is a clinical study titled "A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly". The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 ...
What is the current status of trial NCT04125836?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 135 participants. The study started on 2019-10-10. Estimated completion is 2025-04-24.
What interventions are being tested in trial NCT04125836?
The interventions under investigation include: CAM2029 (octreotide subcutaneous depot) (DRUG).
Who is sponsoring clinical trial NCT04125836?
This trial is sponsored by Camurus AB, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.